John Rademacher: Yes. I guess, let me start by saying, look, we’ve always looked to get rate increase and appropriate. I think the message that we’re trying to deliver there is, the ability for us to actually have the conversations that yield outcome is increasing on the percentage of success, right? You don’t have to go far in picking up a newspaper to understand that everyone is dealing with pretty high inflationary pressures, especially on clinical labor. And so, the ability that we have to bring data and insights to the payer community around some of those pressures and how we need to get offset for those pressures, especially around the nursing costs and the clinical per diems is being received with a different year than it had been historically when we were in low inflation period.
So I can’t say that we’re betting 1,000 by any stretch of the imagination, but our team in market access is focused around making certain that we are having those conversations that we’re looking to take rate into the marketplace. And as we’ve talked about on previous calls, we are always looking at the balance as Mike’s previous comments. There is a free leg to our stool between the reimbursement that we received for the drug and the drug spread, what we get for a clinical per diem and what we get for a nursing rate. And each of our contract was a little bit different in the way in which those — the value that we extract out of those three legs. And so we’re really thoughtful about the way that we approach it. We’re very formulaic in the way that we’re trying to drive that appropriateness.
But it’s not consistent across the board, given that you’ve got these different dynamics on a contract-by-contract or payer-by-payer level. And the team is working to underwrite it in the appropriate way and looking to be able to, again, be able to get rate increases that we feel are appropriate and are in alignment with the additional costs that we’re bearing, as well as the value that we deliver to their members and our patients through the programs that we had administered.
Jamie Perse: Okay. Thanks. And last quick one for me, just on SG&A. It was a little bit higher than, I think, street modeled for this quarter. Is there any seasonality in that? Is that sort of the right base to model for the next few quarters or just any help on if there’s one-time items or any considerations on SG&A? Thank you.
Michael Shapiro: Yeah, nothing really of substance again, I think it did reflect some of the inflationary pressures that flow through the indirect. There is some kind of year end true-ups and things like health benefits, et cetera, where we typically see some adjustments at year end, but nothing really to see there. And again, I think more importantly, Jamie, we continue to see solid leverage in that line as a percent of revenue, which we would absolutely expect going into this year.
Jamie Perse: Okay. Thank you.
Michael Shapiro: Thanks, Jamie.
Operator: Thank you. Our next question comes from the line of Joanna Gajuk with Bank of America. Your line is open.
Joanna Gajuk: Good morning. Thanks for taking the questions. So a couple of follow-ups. So I guess on the last topic around the payer contract in your commentary, I know you’re pushing for better rates. But also, can you kind of step back and talk about your large payers in terms of the contract renewals. Are there any coming up for renewals? When were these contracts last reviewed? And any kind of changes in kind of overall contracting with the commercial payers?
